WXIBF (WuXi Biologics (Cayman)) Shares Buyback Ratio %: -0.67 (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WXIBF WuXi Biologics (Cayman) Inc WXIBF
99 GF Score
Price $6.01
GF Value $5.42
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Shares Buyback Ratio %?

WuXi Biologics (Cayman) WXIBF -3.45% 99 Shares Buyback Ratio % is -0.67 as of Sep. 14, 2026. GuruFocus rates WXIBF with a GF Score™ of 99/100 and a GF Value™ of $5.42 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. WuXi Biologics (Cayman)'s current shares buyback ratio was -0.67%.

WuXi Biologics (Cayman) Shares Buyback Ratio % Related Terms

WuXi Biologics (Cayman) Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Shares Buyback Ratio % Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.27 0.79 -0.76 3.56 -0.67

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 2.45 1.14 0.90 -1.59
WXIBF
99GF Score
WuXi Biologics (Cayman) Inc WXIBF
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Shares Buyback Ratio % Calculation

WuXi Biologics (Cayman)'s Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(4105.938 - 4133.579) / 4105.938
=-0.67%

WuXi Biologics (Cayman)'s Shares Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2025 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Jun. 2025 )
=(4068.902 - 4133.579) / 4068.902
=-1.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -0.67 mean?
WuXi Biologics (Cayman) (WXIBF) has a Shares Buyback Ratio % of -0.67 as of Sep. 14, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Shares Buyback Ratio % too high?
WuXi Biologics (Cayman)'s current Shares Buyback Ratio % is -0.67. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Shares Buyback Ratio % compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Shares Buyback Ratio % of -0.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Shares Buyback Ratio % is -0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.42, compared to a current price of $6.01 — trading 10.9% above its estimated fair value. The current Shares Buyback Ratio % is -0.67. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Shares Buyback Ratio % is -0.67 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued. The current stock price of $6.01 is trading 10.9% above its estimated GF Value™ of $5.42. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Overvalued.

Key valuation signals for WXIBF:

  • Shares Buyback Ratio %: -0.67
  • GF Value™: $5.42 vs. price of $6.01 (10.9% above fair value)
  • GF Score™: 99/100 with 6 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score

Get the complete analysis for WXIBF

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.01
Price
$5.42
GF Value